

LB
JFWPTO/SB/21 (09-04)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages In This Submission

9

Application Number

10/023,933

Filing Date

December 21, 2001

First Named Inventor

Mara NAZARÉ et al.

Art Unit

1621

Examiner Name

S. Kumar

Attorney Docket Number

DEAV2000/A066 US NP

ENCLOSURES (Check all that apply)

☐ Fee Transmittal Form☐ Fee Attached☒ Amendment/Reply☒ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☐ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Reply to Missing Parts/Incomplete Application☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a

Provisional Application

☐ Power of Attorney, Revocation

Change of Correspondence Address

☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) _____☐ Landscape Table on CD☐ After Allowance Communication to TC☐ Appeal Communication to Board of Appeals and Interferences☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☐ Other Enclosure(s) (please identify below):


Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

AVENTIS PHARMACEUTICALS INC.

Signature



Printed name

Joseph D. Rossi

Date

January 13, 2005

Reg. No.

47,038

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-746-4000 ; Total No. of Pages Transmitted: 9)

Signature



Typed or printed name

Paul Irvine

Date

January 13, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Date of Notice of Allowance: December 10, 2004
Serial No: 10/023,933

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Nazare et al.

Examiner: S. Kumar

Art Unit: 1621

Application No.: 10/023,933

Filed: December 21, 2001

Title: NEW OXYBENZAMIDE DERIVATIVES
USEFUL FOR INHIBITING FACTOR XA
OR VLLA

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, on (703) 746-4000

January 13, 2005

Date of Transmission

Signature

Mail Stop Issue Fee
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

**AMENDMENT AFTER ALLOWANCE PURSUANT TO
37 C.F.R. § 1.312**

In response to the Notice of Allowance mailed December 10, 2004, in connection
with the above-captioned patent application, Applicants respectfully request that the
following amendments be entered, without prejudice:

- Amendments to the Claims are reflected in the listing of the claims which begin on page 2 of this paper.
- Remarks/Arguments begin on page 8 of this paper.